Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 621

The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.

Targeting cellular senescence with senotherapeutics: senolytics and senomorphics

Zhang, Lei, Pitcher, Louise E., Prahalad, Vaishali, Niedernhofer, Laura J., Robbins, Paul D.·2023·The FEBS Journal

Abstract

The concept of geroscience is that since ageing is the greatest risk factor for many diseases and conditions, targeting the ageing process itself will have the greatest impact on human health. Of the hallmarks of ageing, cellular senescence has emerged as a druggable therapeutic target for extending healthspan in model organisms. Cellular senescence is a cell state of irreversible proliferative arrest driven by different types of stress, including oncogene‐induced stress. Many senescent cells (SnCs) develop a senescent‐associated secretory phenotype (SASP) comprising pro‐inflammatory cytokines, chemokines, proteases, bioactive lipids, inhibitory molecules, extracellular vesicles, metabolites, lipids and other factors, able to promote chronic inflammation and tissue dysfunction. SnCs up‐regulate senescent cell anti‐apoptotic pathways (SCAPs) that prevent them from dying despite the accumulation of damage to DNA and other organelles. These SCAPs and other pathways altered in SnCs represent therapeutic targets for the development of senotherapeutic drugs that induce selective cell death of SnCs, specifically termed senolytics or suppress markers of senescence, in particular the SASP, termed senomorphics. Here, we review the current state of the development of senolytics and senomorphics for the treatment of age‐related diseases and disorders and extension of healthy longevity. In addition, the challenges of documenting senolytic and senomorphic activity in pre‐clinical models and the current state of the clinical application of the different senotherapeutics will be discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/febs.16350

Cites

176 of 176 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 176 references

Research works printed but not linked: 5

  1. 10.1038/ncomms11190 · DOI · Paper page
  2. 10.18632/aging.101202 · DOI · Paper page
  3. Moll UM, 2003, The MDM2‐p53 interaction, Mol Cancer Res, 1, 1001
  4. 10.1155/2021/5589472 · doi:10.1155/2021/5589472
  5. Tilstra JS, 2011, NF‐kappaB in aging and disease, Aging Dis, 2, 449

Cited by

See all 621

Metadata

Authors
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D.
Venue
The FEBS Journal
Publisher
Wiley
Published
2022-02
Volume
290
Issue
5
Pages
1362-1383
ISSN
  • 1742-464X (ISSN-L)
  • 1742-4658
OpenAlex
W4205869028
Cited by
621
References
176
FWCI
59.16
Type
journal article
Language
en
Open access
closed
Funders
  • Michael J. Fox Foundation for Parkinson's Research (ASAP‐000592)
  • National Institute on Aging (AG063543‐02S1, P01 AG043376, P01 AG062413, RO1 AG063543, U19 AG056278)
  • Glenn Foundation for Medical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. https://app.cochat.ai/papers/10.1111/febs.16350
The paper
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D. (2023). Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. The FEBS Journal. https://doi.org/10.1111/febs.16350

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.